Annovis Bio Inc(ANVS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 7:45 PM ET (Korea 10/28 08:45)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.79 | Insider Own | 11.79% | Shs Outstand | 42.6M | Perf Week | 2.22% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 31.04% | Insider Trans | 1.54% | Shs Float | 37.6M | Perf Month | -27.54% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.3 | Inst Own | 31.56% | Short Float | 15.19% | Perf Quarter | -41.18% |
| Income | -0.05B | P/S | - | EPS this Y | -0.48% | Inst Trans | 4.86% | Short Ratio | 6.69 | Perf Half Y | -45.95% |
| Sales | 0.00B | P/B | - | EPS next 5Y | -2.67% | ROA | -227.74% | Short Interest | 5.72M | Perf YTD | -71.1% |
| Book/sh | -0.1 | P/C | 2.28 | EPS past 3/5Y | 23.23% -10.15% | ROE | -703.68% | 52W High | -81.82% ($5.50) | Perf Year | -53.49% |
| Cash/sh | 0.44 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 7.58% ($0.93) | Perf 3Y | -87.52% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.96% | Gross Margin | - | Volatility(W/M) | 6.71% 7.23% | Perf 5Y | -96.28% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.47 | EPS Q/Q | -23.75% | Profit Margin | - | RSI (14) | 37.47 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.47 | Sales Q/Q | - | SMA20 | -8.02% ($1.09) | Beta | 1.36 | Target Price | $10.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/14 | SMA50 | -23.28% ($1.3) | Rel Volume | 1.07 | Prev Close | $0.96 |
| Employees | 8 | LT Debt/Eq | - | EPS/Sales Surpr. | 11.76% - | SMA200 | -48.68% ($1.95) | Avg Volume(3M) | 0.85M | Price | $1 |
| IPO | 2020/1/29 | Option/Short | Yes/Yes | Trades | 1179 | Volume | 913,333 | Change | 4.49% |
🧠 This is a US clinical-stage biotech company targeting degenerative brain diseases such as Alzheimer's and Parkinson's. It is developing an innovative therapy that protects neurons by inhibiting the production of toxic proteins in the brain through its proprietary drug, Buntanetap.
Over the past 1 year, on the lower side
82% below its 1-year high.
Traded about as much as usual. That is 107% of its average volume.
ANVS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -0.5% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 31.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #425 of 594 in the industry
Based on market cap of $43M.
ANVS#425 Annovis Bio Inc $43M PER - 
SER#426 Serina Therapeutics Inc $42M PER - 
INMB#427 INmune Bio Inc $42M PER - 
GRDX#428 GridAI Technologies Corp $42M PER - 
TVGN#429 Tevogen Inc $41M PER - 
FAQ
What kind of company is ANVS?
ANVS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANVS?
The market cap of ANVS is approximately $43M, ranking 4,921 within its sector.
What is the 52-week high and low for ANVS?
ANVS has recorded a 52-week high of $5.50 and a low of $0.93.
